NCCN Releases First Pediatric Bone Sarcoma Treatment Guidelines

Ewing sarcoma represents the second most common primary bone tumor in children and adolescents, typically manifesting in patients aged 15 to 19. Because symptoms like limb or pelvic pain often mirror common adolescent injuries, the guidelines emphasize the necessity of early diagnostic imaging. While early-stage survival rates reach 81%, the figure falls to 41% for metastatic cases, highlighting the critical need for precise risk stratification and evidence-based intervention.

Patrick Leavey, MD, of UT Southwestern Simmons Comprehensive Cancer Center and chair of the NCCN panel, notes that intensive treatment can deeply disrupt the autonomy of teenagers. These recommendations aim to provide both medical clarity and a sense of support for patients navigating the disease. The guidelines are available for free at NCCN.org, joining a growing library of pediatric resources that includes protocols for Hodgkin lymphoma, Wilms tumor, and soft tissue sarcoma.